- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Nymox Pharmaceutical Corporation is pleased to announce an important upcoming symposium and panel discussion on its first-in-class investigational drug NX-1207, currently in late stage Phase 3 for benign prostatic hyperplasia (BPH) and Phase 2 for Prostate Cancer. The symposium will be held during the 2018 Annual Meeting of the American Urological Association in San Diego CA 3:00 p.m. May 5 in the San Diego Convention Center.